Natural killer (NK) cells, which are innate lymphocytes endowed with potent cytotoxic
activity, have recently attracted attention as potential anticancer therapeutics. While NK cells …

Cholangiocarcinoma is the second most common primary liver cancer. Its incidence is low in
the Western world but is rising globally. Surgery, chemotherapy and radiation therapy have …

Metabolic reprogramming in cancer is not only a biological hallmark but also reveals
treatment vulnerabilities. Numerous metabolic molecules have shown promise as treatment …

Transition metal elements, such as copper, play diverse and pivotal roles in oncology. They
act as constituents of metalloenzymes involved in cellular metabolism, function as signaling …

The therapeutic algorithm of renal cell carcinoma has been revolutionized by the approval of
immunotherapy agents by regulatory agencies. However, objective and durable responses …

N 6-methyladenosine (m 6 A) is the most abundant internal modification in mRNA that
affects RNA processing, stability, and translation. Discovered as the first RNA m 6 A …

The immune checkpoint blockade (ICB) therapy has revolutionized the field of cancer
treatment, while low response rates and systemic toxicity limit its clinical outcomes. With the …

Immune checkpoint inhibitors (ICI) have transformed the therapeutic landscape in oncology.
However, ICI can induce uncommon life-threatening autoimmune T-cell-mediated …

The immune-suppressive tumour microenvironment represents a major obstacle to effective
immunotherapy,. Pathologically activated neutrophils, also known as polymorphonuclear …

Adenosine 5′-triphosphate citrate lyase (ACLY) is a cytosolic enzyme that converts citrate
into acetyl–coenzyme A for fatty acid and cholesterol biosynthesis. ACLY is up-regulated or …